• About us
• Contact

Advertisement

Organisation › Details

Bristol Myers Squibb (BMS) (Group)

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. *

 

	Start	1989-10-04 merged
	Industry	pharmaceutical
	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street 14th Floor
	City	10016 New York, NY
	Tel	+1-212-546-4000
		Address record changed: 2024-01-05
Basic data	Employees	H: 10,001 to 50,00 (2018-12-31)
	Currency	USD
	Annual sales	22,561,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	4,947,000,000 (2018-12-31)
	Cash	6,911,000,000 (2018-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Bristol Myers Squibb (BMS) (Group)

• [1] GlycoEra AG. (1/5/24). "Press Release: GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer". Newton, MA & Wädenswil....
• [2] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....
• [3] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....
• [4] Medicen Paris Region. (4/20/20). "Press Release: Medicen Paris Region Appoints Jessica Leygues as CEO". Paris....
• [5] Cellectis S.A.. (4/13/20). "Press Release: Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer". New York, NY....
• [6] Voluntis S.A.. (3/3/20). "Press Release: Voluntis and Bristol-Myers Squibb to Co-develop Digital Therapeutics for Oncology". New York, NY & Paris....
• [7] MyoKardia, Inc.. (7/18/19). "Press Release: MyoKardia Announces HCM Program Updates". South San Francisco, CA....
• [8] Karuna Therapeutics, Inc.. (4/1/19). "Press Release: Karuna Completes $80 Million Series B Financing". Boston, MA....
• [9] Sanofi S.A.. (2/7/19). "Press Release: Sanofi Delivers 2018 Business EPS Growth of 5.1% at CER". Paris....
• [10] MyoKardia, Inc.. (1/2/19). "Press Release: MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.